RESUMEN
OBJECTIVE: Osteonecrosis (ON), which can lead to physical disability, is a common complication of systemic lupus erythematosus (SLE). The purpose of this study was to determine the prevalence of ON and identify possible risk factors in Chinese SLE patients. METHODS: SLE patients who fulfilled the 1997 American College of Rheumatology SLE classification criteria were recruited from the Peking Union Medical College Hospital. The chi-square test (χ2 test) and multivariate regression analyses were used to evaluate risk factors. The Cox proportional-hazards model was used to construct the survival curves and estimate the simultaneous effects of prognostic factors on survival. RESULTS: We consecutively enrolled 1,158 patients, of which 88 patients (7.6%) developed ON. Among ON patients, 57.1% of patients had isolated femoral head necrosis and 42.9% had multiple joint involvement. The mean age of ON patients (24.62 ± 8.89 years) was significantly younger than SLE patients without ON (27.23 ± 10.16 years, p = 0.09). The ON group presented with a much longer disease course (10.68 ± 5.97 years, p < 0.001) and increased incidence of arthritis, kidney, and central nervous system (CNS) involvement (65.9% [p < 0.05], 57.6% [p < 0.05], and 16.5% [p < 0.05], respectively, in the ON group). ON patients were more likely to be treated with glucocorticoid (GC) and to receive a high dose of prednisolone at the initial stage of SLE (p < 0.05). The percentage of patients who received hydroxychloroquine was much higher in the control group (p < 0.001). Cox regression analysis suggested that CNS involvement and GC therapy were two independent risk factors for ON in SLE patients. The presence of anti-phospholipid antibodies (aPLs) was a risk factor for multiple joint necrosis (odds ratio: 6.28, p = 0.009). CONCLUSIONS: ON remains a serious and irreversible complication in SLE. In addition to glucocorticoid therapy, we found that CNS system involvement was a risk factor for ON, while the administration of hydroxychloroquine was a protective factor. The clinical characteristics of multiple site ON patients were distinct from isolated femoral head necrosis patients. The presence of aPLs was a risk factor for multiple site osteonecrosis.
Asunto(s)
Lupus Eritematoso Sistémico , Osteonecrosis , Adolescente , Adulto , Anticuerpos Antifosfolípidos/sangre , Antirreumáticos/uso terapéutico , China/epidemiología , Estudios de Cohortes , Femenino , Necrosis de la Cabeza Femoral/sangre , Necrosis de la Cabeza Femoral/epidemiología , Necrosis de la Cabeza Femoral/etiología , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Humanos , Hidroxicloroquina/uso terapéutico , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/epidemiología , Masculino , Osteonecrosis/sangre , Osteonecrosis/epidemiología , Osteonecrosis/etiología , Prednisolona/efectos adversos , Prednisolona/uso terapéutico , Prevalencia , Factores de Riesgo , Adulto JovenRESUMEN
The relationship between the appearance of bone metabolism disorders and the onset of steroid-induced osteonecrosis remains unclear. We studied the time course of calcium, phosphorus, osteocalcin, alkaline phosphatase, and mineral density of bone tissue in the subchondral bone of the femoral head of rabbits injected with steroids and attempted to precisely determine the time when disorders in bone metabolism started in animals with steroid-induced osteonecrosis. We detected bone metabolism disorders involved in the early pathogenesis of steroid-induced osteonecrosis, which were the cause, but not the result of this condition.
Asunto(s)
Enfermedades Metabólicas/sangre , Osteonecrosis/sangre , Fosfatasa Alcalina/sangre , Animales , Densidad Ósea/efectos de los fármacos , Calcio/sangre , Femenino , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Metabólicas/metabolismo , Minerales/sangre , Osteocalcina/sangre , Osteonecrosis/tratamiento farmacológico , Osteonecrosis/metabolismo , Fósforo/sangre , Conejos , Esteroides/uso terapéuticoRESUMEN
BACKGROUND: Systemic lupus erythematosus is a multi-organ inflammatory autoimmune disease; immune complexes are part of the pathogenesis, but not entirely responsible. Trisomy X is the most common female chromosomal abnormality and the role of an additional X chromosome in the development of systemic lupus erythematosus is well recognized. However, the potential complications and optimal management of childhood lupus with trisomy X remain unclear. Herein, we describe a case of childhood-onset systemic lupus erythematosus associated with severe bone complications presumably secondary to trisomy X. CASE PRESENTATION: A 16-year-old Japanese girl was diagnosed with childhood-onset systemic lupus erythematosus and trisomy X. A chromosomal abnormality (47, XXX) was incidentally identified on bone marrow examination initially done to determine the cause of pancytopenia. She had a persistent headache, feverãfor six days, diffuse hair loss, mucosal ulcers, butterfly eruptions, and palmar erythema. Furthermore, thrombocytopenia, anemia, and erythrocyte fragmentation were detected, suggesting secondary thrombotic microangiopathy. She was initially treated with intravenous methylprednisolone pulse therapy and prescribed monthly cyclophosphamide for severe disease activity, prednisolone, mycophenolate mofetil, and hydroxychloroquine as remission maintenance drugs. She developed generalized extremity pain that had been worsening throughout the disease. Extremity magnetic resonance imaging performed 12 months after the treatment onset revealed multifocal avascular necrosis, and dual-energy X-ray absorptiometry revealed further decreased bone mineral density. High plasma levels of factor VIII were detected by additional tests for coagulation functions, and we suspected the possibility that factor VIII might cause avascular necrosis due to thrombosis. Currently, she is being treated with prednisolone and MMF for SLE. However, her extremity pain has not been managed effectively even under the administration of non-steroidal anti-inflammatory drugs and pregabalin. CONCLUSIONS: An additional X chromosome has been reported to be associated with factor VIII and osteoporosis. Additionally, elevated plasma levels of FVIII is the risk factors for thrombosis, which leads to the risk of avascular necrosis. Patients with systemic lupus erythematosus complicated by trisomy X might be at a higher risk of avascular necrosis and osteoporosis that can also manifest in childhood systemic lupus erythematosus.
Asunto(s)
Factor VIII/análisis , Lupus Eritematoso Sistémico , Osteonecrosis , Osteoporosis , Pancitopenia/diagnóstico , Aberraciones Cromosómicas Sexuales , Trastornos de los Cromosomas Sexuales del Desarrollo Sexual , Trisomía , Adolescente , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Examen de la Médula Ósea/métodos , Cromosomas Humanos X , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Femenino , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/fisiopatología , Lupus Eritematoso Sistémico/terapia , Administración del Tratamiento Farmacológico , Metilprednisolona/administración & dosificación , Metilprednisolona/efectos adversos , Ácido Micofenólico/administración & dosificación , Ácido Micofenólico/efectos adversos , Osteonecrosis/sangre , Osteonecrosis/diagnóstico por imagen , Osteonecrosis/etiología , Osteoporosis/diagnóstico por imagen , Osteoporosis/etiología , Índice de Severidad de la Enfermedad , Trastornos de los Cromosomas Sexuales del Desarrollo Sexual/diagnóstico , Trastornos de los Cromosomas Sexuales del Desarrollo Sexual/fisiopatología , Trastornos de los Cromosomas Sexuales del Desarrollo Sexual/terapia , Trombosis/sangre , Trombosis/diagnóstico , Trombosis/etiología , Trisomía/diagnóstico , Trisomía/fisiopatologíaRESUMEN
PURPOSE: Early diagnosis is crucial to increase the chances of conservation treatment for patients with steroid-induced osteonecrosis of the femoral head (SIONFH). This study aimed to identify serum peptides as potential biomarkers to diagnose SIONFH. EXPERIMENTAL DESIGN: The serum proteome of 32 SIONFH patients and 24 healthy controls are analyzed using magnetic bead-based weak cation exchange (MB-WCX) and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS). Next, candidate biomarkers are identified using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Candidate biomarkers are then validated using ELISA and western blotting. RESULTS: 39 peaks are identified and the expression fold changes of seven peaks in the two groups are greater than 1.5. Three peaks (m/z: 1077.84 Da; m/z: 1061.78 Da; m/z: 1099.56 Da) tend to be upregulated, while four peaks (m/z: 3973.92 Da; m/z: 7766.53 Da; m/z: 3957.31 Da; m/z: 4212.02 Da) tend to be down-regulated in SIONFH patients. The peak for a 1077.84 Da peptide is identified as Isoform 1 of the Fibrinogen alpha chain precursor (FGA). ELISAs and western blot analyses reveal that the expression of FGA is significantly higher in SIONFH patients than healthy controls. CONCLUSION AND CLINICAL RELEVANCE: FGA is overexpressed in SIONFH patients, and thus, is a novel potential biomarker for SIONFH.
Asunto(s)
Cabeza Femoral/patología , Fibrinógeno/metabolismo , Osteonecrosis/sangre , Proteoma/metabolismo , Esteroides/efectos adversos , Adulto , Biomarcadores/sangre , Estudios de Casos y Controles , Femenino , Cabeza Femoral/efectos de los fármacos , Cabeza Femoral/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Osteonecrosis/inducido químicamente , Osteonecrosis/diagnóstico , Isoformas de Proteínas , Espectrometría de Masa por Láser de Matriz Asistida de Ionización DesorciónRESUMEN
Recently, the role of microRNAs (miRs) in human diseases has been verified. This study was determined to explore the protective effects of microRNA-26a (miR-26a) in steroid-induced osteonecrosis of the femoral head (SONFH) with the involvement of enhancer of zeste homologue 2 (EZH2).Femoral head (FH) samples from SONFH patients and patients with femoral neck fracture were collected, and rat SONFH models were established by Escherichia coli endotoxin combining with large dose steroid pulse assay. The hemorheology, blood lipid, inflammatory factors, and pathologic changes were measured by a series of experiments. Moreover, the detection of osteoblasts, osteoclasts, miR-26a expression, EZH2 expression, osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL), and the apoptosis of osteocytes were conducted. The target relation between miR-26a and EZH2 was clarified by bioinformatics and dual-luciferase reporter gene assay.MiR-26a was poorly expressed, while EZH2 was highly expressed in SONFH, and the elevation of miR-26a could repress EZH2 expression. Elevated miR-26a and reduced EZH2 were able to decelerate the apoptosis of osteocytes, increase osteoblasts, and decrease osteoclasts, resulting in a repression of SONFH progression. Additionally, EZH2 was a target gene of miR-26a. Furthermore, the elevation of EZH2 could reverse the repression of SONFH progression that is induced by elevated miR-26a.We found that up-regulation of miR-26a and knockdown of EZH2 could suppress the development of SONFH, which would contribute to the therapy of SONFH.
Asunto(s)
Proteína Potenciadora del Homólogo Zeste 2/deficiencia , Cabeza Femoral/metabolismo , MicroARNs/genética , Osteonecrosis/genética , Osteonecrosis/terapia , Esteroides/efectos adversos , Animales , Apoptosis , Modelos Animales de Enfermedad , Regulación hacia Abajo , Proteína Potenciadora del Homólogo Zeste 2/genética , Proteína Potenciadora del Homólogo Zeste 2/metabolismo , Femenino , Cabeza Femoral/citología , Cabeza Femoral/patología , Humanos , Inflamación/sangre , Inflamación/inducido químicamente , Inflamación/genética , Inflamación/terapia , Lípidos/sangre , Masculino , Persona de Mediana Edad , Osteocitos/citología , Osteocitos/metabolismo , Osteocitos/patología , Osteonecrosis/sangre , Osteonecrosis/patología , Ratas , Ratas Sprague-Dawley , Regulación hacia ArribaRESUMEN
Traumatic osteonecrosis of femoral head (TONFH) is a common orthopedic disease caused by physical injury in hip. However, the unclear pathogenesis mechanism of TONFH and lacking of simple noninvasive early diagnosis method cause the necessity of hip replacement for most patients with TONFH. In this study, we aimed to identify circulating microRNAs (miRNAs) by integrated bioinformatics analyses as potential biomarker of TONFH. mRNA expression profiles were downloaded from the Gene Expression Omnibus database. Then we combined two miRNA screen methods: Weighted gene co-expression network analysis and fold change based differentially expressed miRNAs analysis. As a result, we identified 14 key miRNAs as potential biomarkers for TONFH. Besides, 302 target genes of these miRNAs were obtained and the miRNA-mRNA interaction network was constructed. Furthermore, the results of Kyoto Encyclopedia of Gene and Genome pathway analysis, Gene Ontology function analysis, protein-protein interaction (PPI) network analysis and PPI network module analysis showed close correlation between these 14 key miRNAs and TONFH. Then we established receiver operating characteristic curves and identified 6-miRNA signature with highly diagnosis value including miR-93-5p (area under the curve [AUC] = 0.93), miR-1324 (AUC = 0.92), miR-4666a-3p (AUC = 0.92), miR-5011-3p (AUC = 0.92), and miR-320a (AUC = 0.89), miR-185-5p (AUC = 0.89). Finally, the results of quantitative real-time polymerase chain reaction confirmed the significantly higher expression of miR-93-5p and miR-320a in the serum of patients with ONFH. These circulating miRNAs could serve as candidate early diagnosis markers and potential treatment targets of TONFH.
Asunto(s)
Biomarcadores/sangre , MicroARN Circulante/genética , MicroARNs/genética , Osteonecrosis/diagnóstico , Adulto , MicroARN Circulante/sangre , Biología Computacional , Femenino , Cabeza Femoral/lesiones , Cabeza Femoral/fisiopatología , Perfilación de la Expresión Génica , Humanos , Masculino , MicroARNs/sangre , Análisis por Micromatrices , Persona de Mediana Edad , Osteonecrosis/sangre , Osteonecrosis/genética , Osteonecrosis/fisiopatología , Mapas de Interacción de Proteínas/genéticaRESUMEN
Bone diseases represent an increasing health burden worldwide, and basic research remains necessary to better understand the complexity of these pathologies and to improve and expand existing prevention and treatment approaches. In the present study, 216 bone samples from the caput femoris and collum femoris of 108 patients with degenerative or dysplastic coxarthrosis, hip fracture, or osteonecrosis were evaluated for the proportion of trabecular bone (TB) and expression of parathyroid hormone (PTH) type 1 receptor (PTH1R), osteoprotegerin (OPG), and receptor activator of nuclear factor kappa-B ligand (RANKL). Serum levels of PTH, OPG, soluble RANKL (sRANKL), alkaline phosphatase (AP), osteocalcin, total procollagen type-1 intact N-terminal propeptide (TP1NP), tartrate-resistant acid phosphatase type 5b (TRAP5b), sclerostin, and C-telopeptide of type-1 collagen (ICTP) were also determined. Age was positively correlated with serum levels of PTH, OPG, and sclerostin but negatively associated with TB and sRANKL. Women exhibited less TB, lower sclerostin and ICTP, and higher TRAP5b. Impaired kidney function was associated with shorter bone decalcification time, less TB, lower sRANKL, and higher serum PTH, OPG, and sclerostin. Furthermore, correlations were observed between bone PTH1R and OPG expression and between serum PTH, OPG, and AP. There were also positive correlations between serum OPG and TP1NP; serum OPG and sclerostin; serum AP, osteocalcin, and TRAP5b; and serum sclerostin and ICTP. Serum OPG was negatively associated with sRANKL. In summary, clear relationships between specific bone metabolism markers were observed, and distinct influences of age, sex, and kidney function, thus underscoring their suitability as diagnostic or prognostic markers.
Asunto(s)
Fracturas de Cadera/patología , Osteoartritis de la Cadera/patología , Osteonecrosis/patología , Adulto , Anciano , Anciano de 80 o más Años , Hueso Esponjoso/metabolismo , Hueso Esponjoso/patología , Femenino , Fracturas de Cadera/sangre , Fracturas de Cadera/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Osteoartritis de la Cadera/sangre , Osteoartritis de la Cadera/metabolismo , Osteocalcina/sangre , Osteonecrosis/sangre , Osteonecrosis/metabolismo , Osteoprotegerina/sangre , Hormona Paratiroidea/sangre , Ligando RANK/sangreRESUMEN
OBJECTIVE: To test whether patients with spontaneous osteonecrosis of the knee (SONK) are characterized by abnormal levels of thrombophilia-associated factors. DESIGN: Twenty-five patients with SONK were recruited. Inclusion criteria were (1) age >40 years, (2) acute onset knee pain not precipitated by trauma, and (3) MRI findings consistent with SONK. Exclusion criteria were (1) history of cancer and chemotherapy and (2) factors associated with secondary osteonecrosis. Blood tests included 13 thrombophilia-associated factors that were either heritable mutations or acquired factors. Descriptive statistics included medians, ranges, means, and standard deviations. Mann-Whitney test was used to compare thrombophilia-associated factor levels between the sexes. Spearman's rank test was used to test correlations between smoking status and each thrombophilia-associated factor. Level of significance was set at 0.05. RESULTS: Median patient age was 62 years (range, 44-77 years). There were 16 (64%) men. Thirteen (52%) patients had thrombophilia-associated factor abnormalities of which 9 were elevated fibrinogen but this was less than 1 standard deviation above norm threshold. Other findings were 3 patients with marginally decreased antithrombin below norm threshold, low protein S Ag in only 1 patient, and factor V Leiden mutation heterozygosity in 2 patients, which was not higher than normal population prevalence. Thrombophilia-associated factors neither differed between sexes ( P = nonsignificant) nor correlated with smoking status ( P = nonsignificant). CONCLUSION: Thrombophilia-associated factor abnormalities in patients with SONK were minimal. Therefore, clinical workup and treatment strategy in this disease should focus on addressing alternative etiologies leading to abnormal subchondral bone metabolism with focal osteopenia.
Asunto(s)
Factor V/análisis , Osteonecrosis/sangre , Trombofilia/complicaciones , Enfermedad Aguda , Adulto , Anciano , Femenino , Humanos , Rodilla/patología , Masculino , Persona de Mediana Edad , Osteonecrosis/etiología , Osteonecrosis/patología , Factores de Riesgo , Trombofilia/sangre , Trombofilia/patologíaRESUMEN
Objective To detect serum levels of interleukin-10 (IL-10) and transforming growth factor-ß1 (TGF-ß1) in patients with systemic lupus erythematosus (SLE) with bone damage, and analyze their clinical significance. Methods The study included 56 patients with SLE. Serum IL-10 and TGF-ß1 levels were detected by ELISA. The clinical data of 56 patients were retrospectively analyzed, mainly recording the cases of osteoporosis and osteonecrosis. According to different bone mass, they were divided into normal bone mass group (14 cases), reduced bone mass group (26 cases) and osteoporosis group (16 cases). According to whether or not there was osteonecrosis, the patients were divided into: no osteonecrosis group (49 cases) and osteonecrosis group (7 cases). SPSS18.0 software was used for statistical analysis. Kolmogorov-smirnov t test whether the data is normally distributed. The measurement data of normal distribution are analyzed by the two-tailed t test. For the measurement data of non-normal distribution, mann-whitney U test was used to analyze. Results Compared to the SLE patients with normal bone mass, SLE patients complicated with osteoporosis lowly expressed TGF-ß1 and highly expressed IL-10. The serum level of IL-10 was higher in SLE patients with osteonecrosis than that in SLE patients without osteonecrosis. No difference was found in the TGF-ß1 between two groups. Conclusion TGF-ß1 level is reduced but IL-10 level is elevated in SLE patients with osteoporosis. Serum IL-10 levels in SLE patients with osteonecrosis are higher than that in those without osteonecrosis.
Asunto(s)
Interleucina-10/sangre , Lupus Eritematoso Sistémico/sangre , Osteonecrosis/sangre , Osteoporosis/sangre , Factor de Crecimiento Transformador beta1/sangre , Estudios de Casos y Controles , Humanos , Lupus Eritematoso Sistémico/complicaciones , Osteonecrosis/complicaciones , Osteoporosis/complicaciones , Estudios RetrospectivosRESUMEN
Avascular necrosis of the femoral head (ANFH) is an a frequently occurring orthopaedic disease with high morbidity. Traditional Chinese Medicine (TCM) Yuanshi Shengmai Chenggu Tablet is a valid prescription for treating steroid-induced femoral head necrosis. However, there are rare investigations about the serum protein marker expression after the acting of drugs on hormone and TCM. In the present study, we aimed to systematically discover and validate the serum biomarkers expression difference in patients with steroid-induced avascular necrosis of femoral head (SANFH) after taking Yuanshi Shengmai Chenggu Tablets (SANFH-TCM), so as to reveal the action mechanism of TCM from the molecular level by using isobaric tags for relative and absolute quantification (iTRAQ) with multiple reaction monitoring quantification. Significant differences in fibrinogen alpha, fibrinogen beta, fibrinogen gamma, fibronectin, C-reactive protein, apolipoprotein A, apolipoprotein D, and apolipoprotein E were found among SANFH, SANFH-TCM, and healthy controls. Therefore, our study proposes potential biomarkers for SANFH diagnosis and for the prognosis of femoral head necrosis after Traditional Chinese Medicine treatment.
Asunto(s)
Biomarcadores/sangre , Proteínas Sanguíneas/metabolismo , Medicamentos Herbarios Chinos/uso terapéutico , Necrosis de la Cabeza Femoral/sangre , Necrosis de la Cabeza Femoral/tratamiento farmacológico , Osteonecrosis/sangre , Osteonecrosis/tratamiento farmacológico , Comprimidos/uso terapéutico , Adulto , Combinación de Medicamentos , Femenino , Cabeza Femoral/efectos de los fármacos , Cabeza Femoral/metabolismo , Humanos , Masculino , Medicina Tradicional China/métodos , Osteonecrosis/metabolismo , Esteroides/farmacologíaRESUMEN
BACKGROUND: The pathophysiology of sickle cell disease (SCD) and the variability of its clinical expression remain not fully understood, whether within or between different SCD genotypes. Recent studies have reported associations between lipid levels and several SCD complications. If lipid levels have been previously described as low in sickle cell anemia (SCA), few data have been provided for sickle cell SC disease (SCC). We designed our epidemiological study to isolate lipid levels and profiles by genotype in Guadeloupian cohorts of SCA and SCC adult patients, at steady state. We compared SCD lipid levels with those of the Guadeloupian general population (GGP), and analyzed potential associations between lipid levels and SCD complications (vaso-occlusive crises, acute chest syndrome and osteonecrosis). METHODS: Lipids, apolipoproteins, biological variables and anthropometric evaluation, were collected at steady state from medical files for 62 SCC and 97 SCA adult patients. Clinical SCD complications were collected from the clinical files. Analysis was conducted by genotype for all variables. RESULTS: Different SCC and SCA lipid profiles, both distinct from their GGP's, were identified. Compared to SCC and GGP, higher triglyceride (TG) levels were observed in SCA patients, independent of hydroxyurea, hemolysis, gender, age, body mass index (BMI), abdominal obesity and clinical nutritional status. Our survey highlights also subsequent anthropometrical phenotypes, with an over-representation of abdominal obesity with normal BMI in SCA patients, and affecting almost exclusively females in both genotypes. Moreover, more frequent positive history of acute chest syndrome (ACS) was observed in SCA patients with TG level higher than 1.50 g/l, and of osteonecrosis in SCC patients having non high-density lipoprotein-cholesterol level (Non HDL-C) higher than 1.30 g/l. CONCLUSIONS: This study reveals that SCA and SCC patients exhibit distinct lipid profiles and suggests that high TG and Non HDL-C levels are associated with past histories of ACS and osteonecrosis in SCA and SCC patients, respectively.
Asunto(s)
Anemia de Células Falciformes/sangre , Lípidos/sangre , Síndrome Torácico Agudo/sangre , Adulto , Índice de Masa Corporal , Estudios de Casos y Controles , Femenino , Guadalupe , Hemólisis , Humanos , Masculino , Persona de Mediana Edad , Osteonecrosis/sangre , Estudios Retrospectivos , Enfermedades Vasculares/sangreRESUMEN
AIM: Osteonecrosis (ON), also known as avascular necrosis, is an important cause of physical disability in rheumatic disease. When this condition affects multiple structures, disability is increased. The purpose of this study was to describe the clinical characteristics of Korean patients with multifocal ON associated with rheumatic disease and to compare them with those of previously reported cases. METHODS: We reviewed the clinical characteristics of eight Korean patients with multifocal ON, defined by the involvement of three or more anatomic sites, associated with rheumatic disease in a single referral academic hospital, and compared them with those of 19 similar cases previously reported in the literature. RESULTS: All eight patients were female, with median age of 26 years. All had underlying systemic lupus erythematosus (SLE) and had been using corticosteroids. The most common site affected by ON was the knee joint. However, in contrast to our patients, the previous reported cases had other rheumatic diseases such as myositis, scleroderma and antiphospholipid syndrome. In comparison between Korean multifocal ON patients with SLE and those of previous reports, shoulder joint involvement was higher in previous reports. Common features in patients from both groups were knee joint involvement and prevalent use of corticosteroids. CONCLUSION: Our findings indicate that multifocal ON is common in young SLE patients who have been using corticosteroids and the most commonly involved site is the knee.
Asunto(s)
Corticoesteroides/efectos adversos , Articulación de la Rodilla/efectos de los fármacos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Osteonecrosis/inducido químicamente , Adolescente , Adulto , Factores de Edad , Autoanticuerpos/sangre , Biomarcadores/sangre , Evaluación de la Discapacidad , Femenino , Humanos , Articulación de la Rodilla/diagnóstico por imagen , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Imagen por Resonancia Magnética , Osteonecrosis/sangre , Osteonecrosis/diagnóstico por imagen , Osteonecrosis/epidemiología , República de Corea/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Pruebas Serológicas , Adulto JovenRESUMEN
BACKGROUND: The objective of this study was to investigate the protective effects of molecular hydrogen, a novel and selective antioxidant, on steroid-induced osteonecrosis (ON) in a rabbit model. METHODS: Sixty rabbits were randomly divided into two groups (model group and hydrogen group). Osteonecrosis was induced according to an established protocol of steroid-induced ON. Rabbits in the hydrogen group were treated with intraperitoneal injections of molecular hydrogen at 10 ml/kg body weight for seven consecutive days. Plasma levels of total cholesterol, triglycerides, soluble thrombomodulin(sTM), glutathione(GSH) and malondialdehyde(MDA) were measured before and after steroid administration. The presence or absence of ON was examined histopathologically. Oxidative injury and vascular injury were assessed in vivo by immunohistochemical staining of 8-hydoxy-2-deoxyguanosine(8-OHdG) and MDA, and ink artery infusion angiography. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays were performed to measure apoptosis. RESULTS: The incidence of steroid-induced ON was significantly lower in hydrogen group (28.6%) than that in model group (68.0%). No statistically differences were observed on the levels of total cholesterol and triglycerides. Oxidative injury, vascular injury and apoptosis were attenuated in the hydrogen group compared with those in the model group in vivo. CONCLUSIONS: These results suggested that molecular hydrogen prevents steroid-induced osteonecrosis in rabbits by suppressing oxidative injury, vascular injury and apoptosis.
Asunto(s)
Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Glucocorticoides/toxicidad , Hidrógeno/farmacología , Osteonecrosis/prevención & control , Estrés Oxidativo/efectos de los fármacos , Angiografía , Animales , Colesterol/sangre , Modelos Animales de Enfermedad , Glutatión/sangre , Humanos , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Incidencia , Inyecciones Intraperitoneales , Masculino , Malondialdehído/sangre , Metilprednisolona/toxicidad , Osteonecrosis/sangre , Osteonecrosis/inducido químicamente , Osteonecrosis/epidemiología , Conejos , Distribución Aleatoria , Trombomodulina/sangre , Triglicéridos/sangreRESUMEN
OBJECTIVE: The aim of this study was to examine the role of coenzyme Q10 (CoQ10) in the prevention of steroid-induced osteonecrosis of the femoral head (ONFH) in rats. METHODS: The study included 20 Sprague-Dawley rats injected once with 20 mg/kg of methylprednisolone acetate into the right gluteus medius muscle to induce osteonecrosis. Animals were divided into two equal groups; Group 1 received no prophylaxis (control group) and the Group 2 received CoQ10. Hematological examinations were performed before steroid injection (0 weeks) and at 4 weeks after steroid injection. Femoral heads were examined histologically to evaluate osteonecrosis. RESULTS: Changes in blood glutathione (GSH) and malondialdehyde (MDA) concentrations were less significant in the CoQ10 group. The incidence of histologic changes consistent with early osteonecrosis was lower in the CoQ10 group (2 of 10; 20%) than the control group (7 of 10; 70%). CONCLUSION: Coenzyme Q10 may be useful as a preventing agent in steroid-induced ONFH. Inhibited oxidative stress is a possible mechanism for this effect.
Asunto(s)
Metilprednisolona/análogos & derivados , Osteonecrosis , Estrés Oxidativo , Ubiquinona/análogos & derivados , Animales , Modelos Animales de Enfermedad , Cabeza Femoral/patología , Glucocorticoides/farmacología , Glutatión/sangre , Malondialdehído/sangre , Metilprednisolona/farmacología , Acetato de Metilprednisolona , Osteonecrosis/sangre , Osteonecrosis/inducido químicamente , Osteonecrosis/patología , Osteonecrosis/prevención & control , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Sustancias Protectoras/farmacología , Ratas , Ratas Sprague-Dawley , Resultado del Tratamiento , Ubiquinona/farmacología , Vitaminas/farmacologíaRESUMEN
We describe thrombosis, deep venous thrombosis (DVT) pulmonary embolism (PE; n = 9) and hip-knee osteonecrosis (n = 5) that developed after testosterone therapy (median 11 months) in 14 previously healthy patients (13 men and 1 woman; 13 Caucasian and 1 African American), with no antecedent thrombosis and previously undiagnosed thrombophilia-hypofibrinolysis. Of the 14 patients, 3 were found to be factor V Leiden heterozygotes, 3 had high factor VIII, 3 had plasminogen activator inhibitor 1 4G4G homozygosity, 2 had high factor XI, 2 had high homocysteine, 1 had low antithrombin III, 1 had the lupus anticoagulant, 1 had high anticardiolipin antibody Immunoglobulin G, and 1 had no clotting abnormalities. In 4 men with thrombophilia, DVT-PE recurred when testosterone was continued despite therapeutic international normalized ratio on warfarin. In 60 men on testosterone, 20 (33%) had high estradiol (E2 >42.6 pg/mL). When exogenous testosterone is aromatized to E2, and E2-induced thrombophilia is superimposed on thrombophilia-hypofibrinolysis, thrombosis occurs. The DVT-PE and osteonecrosis after starting testosterone are associated with previously undiagnosed thrombophilia-hypofibrinolysis. Thrombophilia should be ruled out before administration of exogenous testosterone.
Asunto(s)
Embolia Pulmonar/inducido químicamente , Testosterona/efectos adversos , Testosterona/uso terapéutico , Trombofilia/inducido químicamente , Trombosis/inducido químicamente , Adulto , Anciano , Factores de Coagulación Sanguínea , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteonecrosis/sangre , Osteonecrosis/inducido químicamente , Embolia Pulmonar/sangre , Testosterona/sangre , Trombofilia/sangre , Trombosis/sangreRESUMEN
Multifocal or multiple osteonecrosis (ON), defined by the involvement of 3 or more anatomic sites, is unusual, being observed in only 3%-10% of patients diagnosed with ON. We report the clinical characteristics of a cohort of 29 patients with multifocal ON from a single center and evaluate the prevalence of associated prothrombotic abnormalities in 26 of these patients. We conducted a retrospective study of all patients diagnosed with multifocal ON evaluated in our institution during the last 20 years. We recorded clinical manifestations and underlying diagnoses. A wide thrombophilic profile was performed, including antithrombin, protein C, protein S, lupus anticoagulant, anticardiolipin antibodies, activated protein C resistance, factor V Leiden, mutation G-20210-A of the prothrombin gene, and factor VIII. Coagulation test results were compared with those in a healthy control group and a group of patients with history of lower-extremity deep venous thrombosis. The mean age of the patients was 49.2 ± 15 years (range, 28-81 yr). The mean number of ON localizations per patient was 5.2 ± 2.3 (range, 3-11). Hips were the most commonly affected joint (82%), followed by knees (58%), shoulders (37%), and ankles (13%). Most patients had an underlying disease process, and 12 of 25 (48%) patients had coagulation test abnormalities. The most common alterations were high factor VIII levels and antiphospholipid antibody (aPL) positivity in 24% and 20% of cases, respectively. These abnormalities were more prevalent in patients with multifocal ON compared with patients in the control groups. Sixty-one percent of patients had a history of corticosteroid treatment. Patients with coagulation abnormalities had a higher number of ON localizations per patient (6.5 ± 2.7 vs. 3.88 ± 0.8; p = 0.002) and a higher prevalence of atypical ON localizations (25% vs. 0%; p = 0.05). In conclusion, in the present cohort of patients with multifocal ON, 48% of the patients had at least 1 prothrombotic factor, especially high levels of factor VIII and aPL. These findings have major implications for the diagnosis and treatment of multifocal ON and clearly indicate the need to perform a thrombophilic profile in these patients.
Asunto(s)
Trastornos de la Coagulación Sanguínea/epidemiología , Osteonecrosis/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteonecrosis/sangre , Osteonecrosis/etiología , Prevalencia , Estudios Retrospectivos , Trombosis/sangre , Trombosis/complicaciones , Trombosis/epidemiologíaRESUMEN
OBJECTIVE: To determine whether levels of cryofibrinogen are increased in non-traumatic osteonecrosis (ON) and could correlate with disease staging. METHODS: We prospectively analysed cryofibrinogen levels by immunofixation electrophoresis in 50 patients with non-traumatic ON, 50 healthy volunteers and 8 patients with traumatic ON. Staging of disease involving the femoral heads and the size of necrotic lesions were assessed by the Association Research Circulation Osseous (ARCO) classification system. RESULTS: Mean cryofibrinogen levels in patients with non-traumatic ON were significantly increased relative to healthy controls and to patients with traumatic ON (222.1 ± 20.6, 59.9 ± 5.6 and 52.3 ± 14.9 mg/dl, respectively, P < 0.001). In the non-traumatic ON group, mean cryofibrinogen levels were significantly increased in patients with multifocal ON compared with patients with mono/bifocal ON (276.5 ± 56.5 and 149.3 ± 15.4 mg/dl, respectively, P = 0.03). There were no significant differences in cryofibrinogen levels observed with respect to the size of the necrotic lesions involving the femoral heads. Moreover, cryofibrinogen levels in patients with ON of the femoral heads classified according to the stage of disease were not significantly different between patients with stage 1/2 and patients with stage 3 ON (179.2 ± 31.3 vs 204.1 ± 29.0 mg/dl, respectively; P = 0.813). CONCLUSION: Cryofibrinogen levels are increased in non-traumatic ON and, more importantly, in multifocal ON. The fact that cryofibrinogen levels are not correlated with the size of lesions and the stage of disease could imply systemic rather than local involvement characterizing the pathogenesis of ON.
Asunto(s)
Crioglobulinas/análisis , Fibrinógenos Anormales/análisis , Osteonecrosis/sangre , Adulto , Femenino , Cabeza Femoral/patología , Humanos , Masculino , Persona de Mediana Edad , Osteonecrosis/patología , Índice de Severidad de la EnfermedadAsunto(s)
Anemia de Células Falciformes/sangre , Deformación Eritrocítica , Osteonecrosis/sangre , Anciano , Anemia de Células Falciformes/tratamiento farmacológico , Antidrepanocíticos/uso terapéutico , Femenino , Humanos , Hidroxiurea/uso terapéutico , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Medición de Riesgo , Factores de Riesgo , Adulto JovenRESUMEN
We examined the hypothesis that the factor V Leiden (FVL) and G20101A prothrombin gene mutations are commonly associated with hip osteonecrosis. We prospectively evaluated 244 consecutively referred adults with osteonecrosis (ON), 161 idiopathic and 83 secondary. Cases (n = 244) did not differ from 104 normal controls by race. Of the 244 patients, 23 (9.4%) were FVL heterozygotes versus 2 of 104 controls (1.9%), P = .013, risk ratio (RR) = 4.90, 95% confidence interval (CI) 1.18 to 20.4. Of the 161 patients with idiopathic ON, 15 (9.3%) were FVL heterozygotes versus 2 of 104 normal controls (1.9%), P = .017, RR = 4.84, 95% CI 1.13 to 20.8. Of the 83 patients with secondary ON, 8 (9.6%) FVL heterozygotes versus 2 of 104 normal controls (1.9%), P = .024, RR = 5.01, 95% CI 1.09 to 23.0. Prothrombin gene heterozygosity in normal controls (2.9%) did not differ from ON cases (3.4%), P = 1.0. The thrombophilic FVL mutation is commonly associated with and may be pathoetiologic for hip osteonecrosis.